-0.25 | -1.10%
| Price and Volume | |
|---|---|
| Recent Price | 22.41 |
| 52 Week High | 24.30 |
| 52 Week Low | 11.76 |
| Avg. Daily Vol. (Mil) | 1.51 |
| Beta (3 year) | 2.20 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,870.62 |
| Shares Out (Mil) | 128.10 |
| Float (Mil) | 86.97 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.80 |
| Current Ratio | 1.90 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 29.10 |
| Price/Book | 0.00 |
| Price/Cash Flow | -16.20 |
| Per Share Data | |
| Earnings | -1.63 |
| Sales | 0.77 |
| Book Value | 0.00 |
| Cash Flow | -1.39 |
| Business Summary | |
|---|---|
| Incyte Corporation is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. | |
| General Information | |
| Experimental Station
Route 141 & Henry Clay Road Wilmington, DE 19880 |
|
| www.incyte.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 368 | |
| CEO: Dr. Paul A. Friedman,M.D | |
| Short Interest | |
| Current Month (Mil) | 17.67 |
| Previous Month (Mil) | 16.36 |
| Short Interest Ratio (Days) | 9.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -70.00 |
| Return on Investments | -322.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet